Oral · GLP-1 agonist
Ecnoglutide (VRB-101)
2 trials in this program. Source: ClinicalTrials.gov, as of July 1, 2026.
Distinct formulations of the same molecule
This molecule is developed in parallel as separate programs. They are not competing therapies (they share the same active drug) but differ by formulation, route, and developer. Trials below are labeled with their program code.
- All Ecnoglutide
- Ecnoglutide (XW003): Subcutaneous, Sciwind Biosciences
- Ecnoglutide (XW004): Oral, Sciwind Biosciences
- Ecnoglutide (VRB-101): Oral, Verdiva Bio
Trials
2
Active
2
Recruiting
0
Completed
0
Sites
36
Countries
1
Endpoints
13
Composite endpoints
2
Distinct sites and countries across this program's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
2
2
2
1
1
Trials
Trials for VRB-101
Every trial for this program, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| EVOLVE-2A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Ecnoglutide (VRB-101) Obesity / overweight | BMI 27-30 | Ph 2 | Active, not recruiting | 22 | Jul 2026 | — | |
| NCT07553299A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Ecnoglutide (VRB-101) Obesity / overweight | BMI 27-30 | Ph 2 | Not yet recruiting | 17 | Nov 2026 | — |